Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
Sanara MedTech is back in focus as the consensus fair value estimate edges from US$34.00 to about US$34.33 per share, giving investors a refreshed reference point for the stock. That small move lines up with recent analyst commentary that leans constructive on the company's role in surgical wound and soft tissue management and what that could mean for future execution and valuation work. In the sections ahead, you will see how this evolving narrative fits with updated growth and margin assumptions, and how to track it over time.
Stay updated as the Fair Value for Sanara MedTech shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Sanara MedTech.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Recent coverage of Sanara MedTech has leaned positive, with Freedom Broker initiating the stock with a Buy rating and a US$35 price target. This target sits slightly above the current consensus fair value estimate.
-
Freedom Broker highlights Sanara MedTech's focus on surgical wound and soft tissue products and points to potential growth from broader access and share gains in these categories.
-
The firm also cites the company's efforts to expand its portfolio into adjacent surgical and biologic offerings, which analysts see as adding optionality for future revenue mix and scale.
-
Lake Street's initiation with a bullish view, even without a disclosed target here, reinforces the view that multiple research firms are engaging with the story and building out valuation work around the platform.
🐻 Bearish Takeaways
-
With only a small set of published initiations so far, there is limited visibility into how diverse the analyst opinions are on execution risk, margin trajectory, or potential hurdles to wider adoption of Sanara MedTech's products.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 2 risks for Sanara MedTech. See which could impact your investment.
How This Changes the Fair Value For Sanara MedTech
-
The consensus fair value estimate for Sanara MedTech has shifted from US$34.00 to about US$34.33 per share.
-
Forecast revenue growth has moved from roughly 12.10% to about 13.38%.
-
Expected net profit margin has adjusted from about 6.80% to roughly 4.30%.
-
The future P/E multiple assumption has changed from about 37.3x to roughly 57.6x.
-
The discount rate used in analyst models has edged from 7.90% to about 7.91%.
Never Miss an Update: Follow The Narrative
Narratives connect Sanara MedTech's business story to the underlying forecasts and fair value assumptions analysts are using. They refresh as new data and research arrive, so you can see how the thesis changes over time.
Head over to the Simply Wall St Community and follow the Narrative on Sanara MedTech to stay up to date on:
-
How expanding hospital and distributor relationships, plus underpenetrated specialties outside core ortho and spine, feed into expectations for multi year revenue growth in wound and surgical care.
-
The role of flagship products like CellerateRx, BIASURGE and pipeline assets such as OsStic in broadening Sanara MedTech's addressable market and supporting a higher margin proprietary product mix.
-
Key risks around the THP digital health platform, continued consolidated losses, a concentrated US focus and competition in advanced wound care that could pressure margins and limit diversification.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SMTI .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
